Industry

Provides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3rd CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the … [Read more…]

The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Smart Pills Technology Market By Application, By Target Area, By Disease Indication, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. The Smart Pill Technology Market size was valued at $3.2 billion in 2020 and is estimated to reach $7.5 billion by 2030, growing at … [Read more…]

Kaiser Permanente’s Mid-Atlantic region is the only plan in the nation to receive 5 out of 5 stars for Medicare, Medicaid and commercial health plans from the National Committee on Quality Assurance ROCKVILLE, Md.–(BUSINESS WIRE)–Kaiser Permanente in the Mid-Atlantic region has been named among the highest-rated health plans in the nation according to The National … [Read more…]

German biotech companies at the forefront in the development of nucleic acid-based drugs in the “Leap Innovations” category MUNICH–(BUSINESS WIRE)–On 13 September, the winners of the “Most Innovative Product” award in the category “Leap Innovations” were announced at the “Pharma Trend – Image & Innovation Award”. Cardior Pharmaceuticals came out on top, ahead of RNATICS, … [Read more…]

DALLAS–(BUSINESS WIRE)–$LTRN—Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell … [Read more…]

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in a fireside chat at 1:30 p.m. ET on Friday, September 30, 2022 at the upcoming Jefferies Cell & Genetic … [Read more…]

DecisionDx-Melanoma integrates a patient’s clinicopathologic factors with his/her tumor biology to provide precise, personalized risk estimates, including five-year melanoma-specific survival, recurrence-free survival and distant metastasis-free survival FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal … [Read more…]

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million. New and existing investors, including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, ArrowMark Partners, … [Read more…]

— Multiple tranche debt financing provides Spectrum with up to $65 million — — Funding provides additional capital to optimize commercial launch of ROLVEDON™ — — Cash runway extended through 2024 — BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that … [Read more…]